Author: toxlaw

More intensive hospital care and worse functional outcome are different findings. Historical studies of methamphetamine-associated intracerebral hemorrhage show why an account of “more severe strokes” needs to specify the endpoint. Two California cohorts found important clinical differences while retaining null findings for some discharge outcomes.

What did the 2019 Davis cohort find?

Swor and colleagues retrospectively studied spontaneous primary intracerebral hemorrhage at UC Davis during 2013–2016. The comparison included 41 methamphetamine-positive patients and 201 classified negative by urine testing or recorded history. Mean hospital stay was 18 ± 27 versus 8 ± 8 days; ICU stay was 10 ± 8 versus 5 ± 5 days. These are means and standard deviations, not a prediction for the next patient. Swor et al., 2019.

Both groups had a median discharge modified Rankin Scale (mRS) score of 4. Methamphetamine exposure did not predict the paper’s poor-outcome endpoint, mRS 4–6. The exposed group had less disability before the hemorrhage and a larger deterioration from baseline. The study excluded aneurysm- and arteriovenous-malformation-related hemorrhage. Selective testing, unmeasured social factors and patients dying before diagnosis limit inference. Original report.

What did the 2020 Irvine cohort add?

Zhu and colleagues reviewed 677 spontaneous hemorrhage patients from 2011–2017. They classified 61 as methamphetamine-associated and compared them with 350 having both a negative history and negative urine screen; 266 without testing and denying use were excluded from that comparison. Exposure classification used history or an amphetamine-class urine immunoassay with a 1,000 ng/mL cutoff. Zhu et al., 2020.

At discharge, functional independence (mRS 0–2) was 29.5% versus 25.7% (p=0.534), and mortality was 18.0% versus 24.6% (p=0.267). Neither difference was statistically significant, and length of stay also did not differ significantly. Methamphetamine was not an independent predictor of poor outcome. The single-center retrospective study lacked most patients’ dose, route and duration, could not establish exposure-to-onset timing and acknowledged possible exposure misclassification. Methods and limitations.

Why are those findings compatible?

Hospital stay records time in a healthcare system. Disability scores record functional status at an assessment. A difference in one endpoint can coexist with a null finding in the other. Discharge destination, recovery needs and the starting level of function also affect how a hospital course should be understood.

Consider two hypothetical patients who reach the same disability category at discharge. If one was independent before the event while the other already required help, their final categories are identical but their losses differ. That arithmetic does not prove a drug mechanism; it explains why baseline-to-discharge change and discharge status answer separate questions.

The papers also used different outcome definitions. “Poor outcome” at mRS 4–6 is not simply the complement of “functional independence” at mRS 0–2: mRS 3 lies between those boundaries. Combining reported percentages without retaining their thresholds would silently change the analysis.

Does a null outcome comparison mean no stroke risk?

No. These comparisons begin with people who already had a hemorrhage. They address the subsequent course among selected hospitalized patients, not the probability of developing hemorrhage among exposed and unexposed populations. A null association after admission cannot resolve the upstream occurrence question.

Nor does a nonsignificant p value establish clinical equivalence. The studies were observational, and exposure classification was imperfect. For an individual assessment, the useful questions are which hemorrhage subtype occurred, how exposure was established, when the relevant events happened and which outcome is being claimed. The methamphetamine-associated label is a study grouping; it does not prove that the drug caused every included hemorrhage.

Sources

Swor DE, Maas MB, Walia SS, et al. Clinical characteristics and outcomes of methamphetamine-associated intracerebral hemorrhage. Neurology. 2019;93:e1–e7. doi:10.1212/WNL.0000000000007666.

Zhu Z, Osman S, Stradling D, Shafie M, Yu W. Clinical characteristics and outcomes of methamphetamine-associated versus non-methamphetamine intracerebral hemorrhage. Scientific Reports. 2020;10:6375. doi:10.1038/s41598-020-63480-z.

A prescription-amphetamine dose association can be clinically important without establishing a universal safe dose or predicting a particular patient’s outcome. A 2024 case-control study is especially instructive because its headline result depends on three details: the selected psychiatric population, a combined psychosis-or-mania outcome and a standardized dose scale.

What was actually compared?

Moran and colleagues compared 1,374 patients aged 16–35 hospitalized for incident psychosis or mania with 2,748 patients undergoing an initial psychiatric hospitalization for other reasons at McLean Hospital, using 2005–2019 records. Past-month prescription amphetamine exposure was associated with an adjusted odds ratio of 2.68 (95% CI 1.90–3.77) relative to no exposure. Above 30 mg/day dextroamphetamine equivalents, the estimate was 5.28 (3.06–9.13). Moran et al., 2024.

The investigators multiplied mixed amphetamine salts doses by 0.75 and lisdexamfetamine doses by 0.3. Thus, “30 mg” referred to equivalents, not every product’s labeled milligrams. The high-dose category contained 50 cases and 35 controls. Dose was missing for 53 of 415 exposed patients. Methylphenidate’s estimate was 0.91 (0.54–1.55), without a statistically clear association. Hospitalized control selection, incomplete information and residual confounding constrain causal inference. Methods, Table 2 and limitations.

Why cannot 50 cases out of 85 establish incidence?

The investigator selected people according to whether they belonged to the case or control group. The resulting fraction of cases among high-dose subjects therefore reflects that sampling process. It does not describe what happened to a population of 85 initially unaffected high-dose patients followed forward in time.

This is also why “5.28-fold odds” must not become “a 5.28-fold probability” or “five in every hundred patients.” An absolute probability needs a suitable starting risk and a study design that supports that calculation. Applying an arbitrary baseline would introduce information the paper did not establish for the patient under review.

Why does the dose scale matter?

Using the study’s arithmetic, 40 labeled milligrams of mixed amphetamine salts corresponds to 30 mg equivalents, whereas 30 labeled milligrams corresponds to 22.5 mg equivalents. These are illustrations of the published classification method, not instructions for switching medicines or assertions that formulations have identical effects. A report that compares a prescription directly with the study’s boundary should show the product, daily dose and conversion.

The boundary also separates categories used for analysis. A category boundary does not demonstrate a biological cliff: crossing it does not establish that a new effect begins at that exact milligram, and being below it does not establish an absence of risk. The confidence interval describes uncertainty around a group estimate, not the range of possible outcomes for one patient.

What must remain separate in an individual case?

Psychosis and mania were combined in the main outcome, so the headline number should retain both terms. Neither outcome is interchangeable with a toxicology finding, a general impression of agitation or a conclusion about driving performance.

A useful individual assessment separates the prescription record from evidence of ingestion, then aligns reported symptoms with treatment changes, other exposures and the clinical course. The association provides a reason to examine that chronology carefully. It does not by itself establish that the medication caused the episode, that the person misused it or that a detected concentration proves impairment.

This article interprets historical observational evidence published in 2024. The numerical boundary is a research classification, not a current prescribing guideline or a stand-alone rule for medical or legal decisions.

Source

Moran LV, Skinner JP, Shinn AK, et al. Risk of Incident Psychosis and Mania With Prescription Amphetamines. American Journal of Psychiatry. 2024;181:901–909. doi:10.1176/appi.ajp.20230329. Full-text manuscript.

Two frequently persuasive forms of evidence—a large human database and an experiment that produces disease—can still leave an individual causal question unresolved. Research on amphetamines and aortic dissection illustrates the problem. The human study identifies an association; the animal study tests a deliberately sensitized vascular system. Neither supplies a percentage risk for a particular person after a particular dose.

What did the human study measure?

Westover and Nakonezny analyzed 30,922,098 hospital discharges for adults aged 18–49 in the 1995–2007 Nationwide Inpatient Sample. They identified 3,116 principal diagnoses of thoracic or thoracoabdominal aortic dissection. Amphetamine abuse/dependence coding was associated with dissection after adjustment: odds ratio 3.33, 95% confidence interval 2.37–4.69. This is historical administrative evidence, published in 2010. Original study.

The exposure codes could encompass methamphetamine, amphetamine or ecstasy. They did not identify a verified methamphetamine dose, route, blood concentration or interval before symptoms. The database counted discharges rather than unique people, and repeat admissions could not be identified. Coding validity and residual confounding limit interpretation. The result does not characterize routine therapeutic amphetamine prescribing. Methods and limitations.

An odds ratio is a comparison between groups defined by the study. It is not the fraction of exposed people who developed disease, and it cannot be converted to an individual’s probability without an appropriate baseline and matching population. A very large discharge count improves the ability to study an uncommon diagnosis; it does not supply missing exposure measurements.

What happened in the rat experiment?

Luo and colleagues used three-week-old male Sprague-Dawley rats. Their 2022 experiment combined methamphetamine with β-aminopropionitrile (BAPN), an inhibitor used to weaken aortic-wall integrity. BAPN was given intragastrically at 1 g/kg every 24 hours; methamphetamine was injected intraperitoneally at 5 mg/kg twice daily. The combination schedule comprised two weeks of BAPN, two weeks of both agents, then two weeks of methamphetamine alone. Luo et al.

The 60% outcome was 12/20 animals: three aneurysms, five dissections and four fatal ruptures with hemothorax. Methamphetamine alone raised blood pressure but produced no thoracic aneurysm/dissection in that experimental group. BAPN alone produced an event in 1/6 rats. Human aortic tissue examined in the paper did not come from patients with known methamphetamine abuse. Shared molecular findings therefore did not validate methamphetamine-specific human causation. Experimental findings and limitations.

Why does preconditioning change the inference?

The experimental question concerns the effect of a drug within a vascular system altered by another intervention. Removing the preconditioning from a description changes that question. Likewise, combining aneurysm, dissection and fatal rupture into one percentage makes the outcome broader than dissection alone. The numerator and the experimental background both belong beside the 60% figure.

The methamphetamine-only result also deserves explicit reporting. A null result in that group cannot establish human safety: species, developmental stage, exposure schedule and sample size constrain it. But omitting it would make the experiment appear to show that methamphetamine alone reliably caused the reported lesions.

What can the two studies contribute to a forensic assessment?

The studies address complementary levels of evidence. The discharge analysis asks whether diagnoses co-occur more often than expected after measured adjustment. The rat experiment investigates biological effects under controlled, unusual conditions. Combining them can strengthen the rationale for considering a contribution, but it does not erase the differences in exposure definition or establish what happened in an individual aorta.

A case-specific analysis still needs the lesion’s clinical and pathological characterization, the exposure chronology and competing explanations. A positive toxicology result supplies exposure evidence; neither publication makes it a stand-alone test of the cause, timing or mechanism of a person’s dissection.

Sources

Westover AN, Nakonezny PA. Aortic Dissection in Young Adults Who Abuse Amphetamines. American Heart Journal. 2010;160:315–321. doi:10.1016/j.ahj.2010.05.021.

Luo BY, Zhou J, Guo D, et al. Methamphetamine induces thoracic aortic aneurysm/dissection through C/EBPβ. Biochimica et Biophysica Acta—Molecular Basis of Disease. 2022;1868:166447. doi:10.1016/j.bbadis.2022.166447.

A kidney-biopsy series can describe serious injury in people with a methamphetamine history without estimating how often that injury develops among everyone who uses the drug. That distinction controls the interpretation of a striking 97% finding in a 2024 study. A separate biopsy-confirmed case also illustrates why proving a tissue lesion does not automatically prove its cause.

Who was included in the 97% denominator?

Choung and colleagues retrospectively examined 112 adult native-kidney biopsies from 2013–2023. Clinicians had considered methamphetamine a possible contributor. In the 62-person reportedly methamphetamine-only group, 60 had kidney dysfunction at biopsy. This was a selected clinical series, without an unexposed comparison group. Urine toxicology was available for only 26 of all 112 patients and was positive in 22. Exposure duration was poorly documented. Choung et al., 2024.

The denominator therefore starts after several selection steps: a person develops a clinical problem, reaches specialist evaluation, undergoes biopsy and has a relevant exposure history recorded. People with uncomplicated exposure or problems that did not prompt biopsy are outside that denominator. Dividing 60 by 62 answers a question about the selected biopsy group; it cannot supply a population probability of methamphetamine-associated kidney dysfunction.

Several diagnoses could coexist in one biopsy

These categories overlap. Myoglobin casts occurred in 8 of the 41 acute-tubular-necrosis cases; the reported 19% uses that subgroup denominator. The article’s body and tables identify 50 patients with additional substance use, despite “60” in its abstract. The body totals reconcile with 112. Infection, diabetes and hypertension complicate attribution. Source and tables.

What did a biopsy-confirmed TMA case establish?

Nagaoka and colleagues described a 47-year-old man with severe kidney dysfunction, hypertension and later heart failure. Initial creatinine was 7.61 mg/dL and blood pressure 192/100 mm Hg. On readmission, blood contained methamphetamine 333 ng/mL and amphetamine 14.1 ng/mL. Kidney biopsy demonstrated thrombotic microangiopathy (TMA), a vascular injury pattern. The authors favored methamphetamine as the cause. Nagaoka et al., 2024.

They nevertheless reported that clinical TMA criteria were not met. No fragmented red cells were observed; haptoglobin was not measured, genetic TMA testing was not performed and antiphospholipid antibodies were not examined. Hypertension remained a possible contributor. Improvement followed cessation and medical treatment, leaving those influences intertwined. This single human case establishes neither a frequency nor a causal blood-concentration threshold. Case report.

How should a case-specific opinion use this evidence?

Keep three propositions separate: the tissue shows an injury pattern; the patient had documented exposure; and the exposure caused or contributed to that injury. The first two may support the third, but they do not complete it. A useful record review aligns specimen collection with symptoms, biopsy timing, blood pressure, infections, other medications and the subsequent course. The cohort supplies a differential diagnosis to investigate, while the case supplies an example of attribution under incomplete exclusion of alternatives.

These are historical observational findings, not a controlled exposure experiment or a current treatment guideline. They warrant attention to renal injury while preserving the difference between clinical suspicion, morphological diagnosis and demonstrated drug causation.

Sources

Choung HYG, Nast CC, Haas M, et al. Spectrum of Kidney Biopsy Findings Associated With Methamphetamine Use. Kidney International Reports. 2024;9:2180–2188. doi:10.1016/j.ekir.2024.04.049.

Nagaoka K, Katagiri D, Matsunami M, et al. Kidney Biopsy Proven Thrombotic Microangiopathy Induced by Methamphetamine. Internal Medicine. 2024;63:1603–1608. doi:10.2169/internalmedicine.2143-23.

Evidence of tissue injury and an opinion about what caused that injury are related but separate propositions. A 2025 report of gastrointestinal illness in a person with methamphetamine exposure offers a concrete example of that distinction. The case is informative without being a controlled experiment or a validated diagnostic rule.

What did the case report document?

Johnsen and colleagues described one 48-year-old man with two weeks of episodic abdominal pain, nausea and hematemesis. Urine confirmation reported methamphetamine at 988 ng/mL and amphetamine at 776 ng/mL. CT findings prompted concern for malignancy; endoscopy identified ulceration and diffuse mucosal pallor without masses or strictures.

Upper-tract biopsies showed inflammation and intestinal metaplasia without dysplasia or malignancy. H. pylori staining was positive at the gastroesophageal junction but negative in the antral ulcer. No colonic biopsies were obtained. The authors attributed the diffuse presentation to methamphetamine-associated ischemia. The patient was lost to follow-up, so the planned repeat endoscopy did not establish healing after cessation. This was a single clinical attribution, not a measured dose-response or experimental demonstration of causation.

Why should the pathology and causal opinion be quoted separately?

A report may contain direct observations, interpretations of those observations and a final clinical impression. A careful summary identifies which is which. Describing a biopsy as having “proved methamphetamine injury” would require evidence that the observed tissue pattern uniquely identified that drug as the cause.

This is a methodological distinction, not a finding that the treating team’s interpretation was wrong. Clinical reasoning commonly combines several kinds of evidence. A forensic assessment should make that reasoning visible so another reviewer can examine the assumptions connecting observation to attribution.

What does the toxicology contribute?

The specimen and analyte must remain attached to the result. A urine concentration should not be relabeled as a blood concentration or treated as a directly measured dose. Nor does confirmation alone supply an exact time of use or quantify functional impairment at a different event.

These distinctions matter particularly when a chronology is disputed. Before making a timing claim, identify the evidence used to establish the sequence of exposure, symptoms, testing and treatment. State uncertainty where the sequence is incompletely documented.

Does improvement after treatment prove a proposed cause?

To evaluate a claimed response to removal of an exposure, first establish that the relevant follow-up observation actually occurred. A scheduled test is different from a completed test. A plan to check recovery cannot be reported as evidence of recovery.

Even when follow-up exists, interpretation should consider the other interventions and changes occurring during the same period. A temporal sequence can support an explanation without uniquely identifying it.

How can this case be used responsibly?

It can illustrate a possible presentation and the reasoning used in one evaluation. It cannot provide a frequency estimate, establish a concentration threshold for gastrointestinal injury, or resolve another patient’s differential diagnosis by analogy alone.

For record review, request the original pathology report, toxicology method and specimen information, imaging and endoscopy reports, treatment chronology and completed follow-up. The purpose is to distinguish documented findings from assumptions added later.

Scientific source

Johnsen N, Chang A, Chuang K, Patel S, Wu S. A Rare Case of Methamphetamine-Induced Diffuse Gastrointestinal Ischemia. Cureus. 2025;17(1):e76857. Published January 3, 2025. Single human case report. DOI: 10.7759/cureus.76857. Publisher full text.

A survival curve can refer to remaining alive, remaining free of a defined event, or another specified outcome. Those labels are consequential. A historical study of methamphetamine-associated pulmonary arterial hypertension, or PAH, shows why the endpoint definition must accompany the percentage.

What did the cohort actually measure?

Zamanian and colleagues prospectively studied 90 patients with (meth)amphetamine-associated PAH and 97 with idiopathic PAH at Stanford during 2003–2015. The composite outcome included death, transplantation or hospitalization for right-ventricular failure. Estimated five-year event-free survival was 47.2% versus 64.5%, respectively. The adjusted hazard ratio was 2.04 (95% CI, 1.28–3.25).

The associated group had 52 events: 31 deaths, three transplants and 18 right-ventricular-failure hospitalizations. Thus, event-free survival was not an all-cause-survival percentage. The study was observational and single-center, with treatment practices evolving during recruitment. Dose thresholds for pulmonary toxicity were not established, and administration routes were incompletely captured. Separate hospitalization-code analyses were not estimates of population disease prevalence.

Why is “more than half died within five years” an unsupported rewrite?

Subtracting an event-free percentage from 100 gives an estimated proportion with the defined event, subject to the study’s survival-analysis framework. It does not transform a composite endpoint into death alone. A nonfatal component remains nonfatal when the endpoint is summarized.

Nor can the cumulative count of deaths during a study simply be substituted for a fixed-time Kaplan–Meier estimate. The denominator and observation times must match the calculation being proposed. A reviewer should ask which quantity is being quoted before comparing percentages from different reports.

Is a hazard ratio an individual’s chance of dying?

No. A hazard ratio describes a relative time-to-event comparison under a model. It is neither an absolute probability nor automatically a causal effect. Applying it to a particular person requires additional reasoning about the relevant population, outcome and time horizon.

Adjustment can address specified measured differences. It does not convert an observational exposure comparison into random assignment, or establish that every possible confounder was measured accurately. An expert interpretation should explain what the analysis supports without assigning it a stronger design than it had.

Which clinical question does this study address?

A prognosis comparison among people already diagnosed with a condition is different from the risk of developing that condition among everyone exposed to a drug. To move between those questions, one needs a suitable population at risk and evidence about disease occurrence.

For the same reason, a cohort comparison cannot establish that a positive drug test diagnosed PAH or identified the cause of an individual’s symptoms. Exposure classification, disease diagnosis and prognosis are separate evidentiary steps.

How should the historical result be presented?

Keep the endpoint definition beside the number. Identify the comparator as idiopathic PAH, rather than an unaffected general population. Label the evidence as a historical observational cohort and explain why it may or may not fit the question under review. This article interprets that study’s reporting; its historical disease definitions are not presented as current diagnostic guidance.

Scientific source

Zamanian RT, Hedlin H, Greuenwald P, et al. Features and Outcomes of Methamphetamine-associated Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. 2018;197(6):788–800. Historical prospective clinical cohort with a separate administrative-data analysis. DOI: 10.1164/rccm.201705-0943OC. Primary full text.

A plausible biological mechanism is a reason to test a treatment. Whether the treatment helps requires a comparison on the outcome of interest. A 2021 trial of N-acetylcysteine, or NAC, illustrates why improvement during a study should be separated from improvement attributable to the assigned medication.

What did the historical human trial test?

McKetin and colleagues randomized 153 adults with methamphetamine dependence to take-home oral NAC, 2400 mg/day (76 participants), or placebo (77), for 12 weeks. Primary outcomes were self-reported use days over four weeks and weekly methamphetamine-positive oral-fluid samples. Intention-to-treat analyses used imputed missing data.

Mean reductions in use days were 6.8 with NAC and 7.3 with placebo. The group difference was 0.5 days, with a 97.5% confidence interval of −3.4 to 4.3. The oral-fluid difference was also nonsignificant: −2.6 percentage points (97.5% CI, −12.6 to 7.4). Craving, dependence and withdrawal outcomes did not show significant advantages. Adherence was imperfect, and oral-fluid collection differed between groups. The authors cautioned that these results did not exclude benefits in other settings, such as relapse prevention after abstinence.

Why is improvement in the NAC group insufficient?

The question in a placebo-controlled experiment is whether the assigned intervention adds benefit relative to its comparator. If one describes only the improvement in the active group, the comparison that motivated randomization disappears from the account.

This is a general interpretive point, rather than an explanation of why any particular participant improved. Changes during a trial can have several explanations. Assigning them all to the medication requires evidence beyond the fact that medication was provided.

How should the null finding be described?

“No significant difference” and “the treatments are identical” are different statements. The confidence interval describes the uncertainty surrounding an estimated difference. It should remain visible when a conclusion is expressed in everyday language.

It is also important to retain the actual confidence level. Replacing a reported 97.5% interval with the more familiar label “95%” would misstate the analysis even if the numerical endpoints were copied correctly. A scientifically careful summary preserves the interval, unit and outcome together.

Does a glutamate rationale establish clinical benefit?

The supplied 2025 McKetin narrative review discusses NAC among pharmacotherapies directed at the cystine/glutamate exchange system and describes disappointing clinical results. That review supplies a research context; the randomized trial supplies the direct comparison summarized here.

Mechanistic reasoning and clinical testing have complementary roles. A proposed pathway can guide the choice of an intervention or endpoint. It cannot substitute for the result of the experiment designed to test that intervention. Conversely, a negative trial should be scoped to what was actually tested rather than expanded into a claim that all research on the pathway is futile.

What belongs in a useful evidence summary?

Identify the population, regimen, comparator, measured outcomes and missing-data approach. Report the between-group finding before offering an explanation. Distinguish a hypothesis for future study from an observed treatment effect. This preserves the contribution of negative evidence without overstating its reach.

Scientific sources

McKetin R, Dean OM, Turner A, et al. N-acetylcysteine (NAC) for methamphetamine dependence: A randomised controlled trial. EClinicalMedicine. 2021;38:101005. Historical randomized human trial. DOI: 10.1016/j.eclinm.2021.101005. Primary full-text record.

McKetin R, Kim JH, Turner A, Berk M. Methamphetamine Pharmacotherapy: A Need to Re-focus on the Complex Neurobiological Changes that Occur Both During and After Methamphetamine Use Disorder. CNS Drugs. 2025;39:1061–1070. Supplied narrative review/current opinion. DOI: 10.1007/s40263-025-01214-3.

A treatment can show a benefit on its primary endpoint without demonstrating a benefit on every other outcome. The challenge is to describe the result precisely enough that readers can see both its value and its limits. A 2026 phase 3 mirtazapine trial provides an example involving methamphetamine use days, biological testing and tolerability.

What was randomized, and what changed?

McKetin and colleagues randomized 344 adults at six Australian outpatient clinics; 339 received study medication, comprising 172 assigned mirtazapine and 167 placebo. Oral mirtazapine was 30 mg/day for 12 weeks. At week 12, modeled self-reported use days in the preceding 28 days declined by 7.0 with mirtazapine and 4.8 with placebo: a between-group difference of −2.2 days (95% CI, −4.2 to −0.2; P = .02).

Methamphetamine-negative oral-fluid samples were 13.2% versus 12.0%, an estimated 1.3-percentage-point difference (95% CI, −4.7 to 7.2; P = .68). Other overall secondary endpoints were not significant. Drowsiness occurred in 80/172 versus 55/167, and reported weight gain in 17/172 versus 5/167. Medication discontinuation for adverse reactions was 40/172 versus 25/167, without a statistically significant difference. Limitations included self-reported use, imperfect adherence and discontinuation. The authors’ June correction concerned a surname in the visual abstract.

Why is the treatment effect different from the total improvement?

The comparison of interest is the difference between assigned groups, rather than the entire change in one group. Reporting the full decline in the medication group as though all of it were attributable to medication would omit the improvement observed with placebo.

Arithmetic also matters when describing the outcome. A difference expressed in days per 28-day period is not a number of people achieving abstinence. It cannot be turned into an abstinence success rate merely by attaching a percentage sign.

Does the oral-fluid result invalidate the primary finding?

A careful appraisal should first identify what each endpoint measures and how it was analyzed. An interview covering a period of time and specimens collected at particular visits are different observation schemes. Disagreement between their statistical results calls for examination of the methods; it does not, by itself, prove dishonesty, establish that one measurement is error-free, or justify deleting the unfavorable endpoint from a summary.

The appropriate description preserves both results. A statistically significant primary comparison should not be dismissed simply because another comparison is nonsignificant. Equally, the primary result should not be expanded into an assertion that all corroborating tests improved.

How does this fit the supplied research collection?

The supplied 2025 McKetin review considers the limitations of maintenance pharmacotherapies and argues for attention to withdrawal, longer-term function and relapse. That is a narrative research perspective, not the new trial itself. Its emphasis helps frame a useful question: which aspect of recovery did a particular experiment measure?

For a case assessment or research summary, separate changes in use frequency, biological tests, daily function and adverse effects. Do not presume that improvement in one establishes improvement in the others. Nor does assignment to a treatment establish an individual’s impairment status at a separate event.

This article interprets study design and reporting. It does not prescribe mirtazapine or recommend changing medication.

Scientific sources

McKetin R, Shoptaw S, Saunders L, et al. Mirtazapine for Methamphetamine Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2026;83(6):581–589. Primary randomized human treatment trial; published online April 1, 2026. DOI: 10.1001/jamapsychiatry.2026.0159. Publisher full text. Visual-abstract correction.

McKetin R, Kim JH, Turner A, Berk M. Methamphetamine Pharmacotherapy: A Need to Re-focus on the Complex Neurobiological Changes that Occur Both During and After Methamphetamine Use Disorder. CNS Drugs. 2025;39:1061–1070. Supplied narrative review and current-opinion article, published September 14, 2025. DOI: 10.1007/s40263-025-01214-3.

A confirmed methamphetamine result identifies an analyte in the submitted specimen. A claim that the person deliberately took a second drug adds a source-and-behavior inference. A 2025 Swedish investigation is useful because it examined a pattern that can make that inference difficult: substantial urinary amphetamine with very little methamphetamine.

What did the primary study actually examine?

Helander, Andersson and Villén reviewed 12,062 routine urine confirmation results following positive amphetamine-class screens. Amphetamine was reportable in 10,371 samples; methamphetamine in 259, using a 200 μg/L reporting limit. Among those 259, 69% had methamphetamine below 2% of the amphetamine concentration.

Selected chiral analyses included eight medication-associated urine samples containing d-amphetamine and 2.2–22.9 μg/L d-methamphetamine, representing 0.01–0.06% of amphetamine. One Elvanse capsule preparation and one Attentin tablet preparation had no methamphetamine detected. The authors interpreted these findings as support for trace N-methylation of amphetamine. This was observational laboratory evidence with selected follow-up samples, not a controlled tracer demonstration establishing the pathway in every person. “Not detected” describes the analytical result, rather than an absolute absence at every possible sensitivity.

Why do the denominators and units matter?

The 259 reportable methamphetamine results and the eight selected medication-associated samples answer different questions. The former describes a laboratory testing series; the latter explores an explanatory pattern. Treating eight selected samples as eight randomly sampled medication users would add a sampling assumption that needs its own support.

Likewise, a proportion must identify both numerator and denominator. A methamphetamine-to-amphetamine percentage is different from a percentage of people who took methamphetamine. A small concentration ratio cannot be relabeled as a small probability of separate ingestion without a model connecting those quantities.

For unit checking, 1 μg/L equals 1 ng/mL. Converting the label does not change the concentration or make a low-level finding more substantial. Keep both analytes in matching units before calculating any ratio.

Does this establish an innocent explanation for every low result?

No. The appropriate methodological conclusion is that a proposed explanation must be evaluated against the actual evidence. Demonstrating that an alternative is plausible does not identify which explanation operated in an individual specimen. Conversely, the mere existence of an analytically confirmed peak does not supply the missing evidence about its source.

A defensible assessment should distinguish the laboratory identification, the proposed origin, and the claimed conduct. Each step should state its assumptions and what evidence could distinguish competing explanations. That approach permits a conclusion to remain uncertain when the available measurements cannot resolve it.

What should be reviewed in an actual testing dispute?

Request the quantitative results for both analytes, the reporting and quantification limits, relevant blanks and carryover checks, dilution records, medication information, and any chiral data. These are suggested review steps, not findings that a particular laboratory made an error. If a product explanation is proposed, identify the actual product evidence supporting it rather than treating a drug name as proof about a particular batch.

The study concerns urine source interpretation. It should not be converted into a blood concentration, an exact ingestion time, a dose estimate, or proof of impairment at an earlier event.

Scientific source

Helander A, Andersson A, Villén T. Origin and Interpretation of Low Methamphetamine Levels Found in Amphetamine-Positive Urine Samples: Support for Methylation of Amphetamine as a Minor Metabolic Pathway. Drug Testing and Analysis. 2025;17:2276–2282. Published August 7, 2025. Primary observational laboratory study. DOI: 10.1002/dta.3940. Publisher full text.

A behavioral effect can decline while a laboratory still detects a drug. Conversely, detecting a drug does not by itself identify a particular behavior. A mouse time-course experiment offers a focused example of why these endpoints should be described separately.

What was measured in the animal experiment?

Su and colleagues used 64 male C57BL/6 mice: seven methamphetamine groups and one saline group, eight per group. A single 2.0 mg/kg intraperitoneal dose of d-methamphetamine was followed by movement measurements and terminal heart-blood and brain collection at specified times from five minutes through eight hours.

Blood methamphetamine peaked at the earliest sampled time, five minutes; brain methamphetamine and amphetamine peaked at 30 minutes. Movement exceeded saline controls through two hours, but comparisons at four and eight hours were not significant in the Results section. Both analytes remained detectable in brain at eight hours. Later discussion language about four-hour activity is not fully consistent with that reported comparison. These results concern movement in male mice, not human driving or a human impairment cutoff.

Why does “peak at five minutes” need qualification?

When sampling begins after administration, the largest observed value identifies a maximum among the observations. Establishing the exact biological maximum requires enough sampling to locate it. A reader should therefore ask whether “peak” refers to an observed sampling point, a fitted model estimate, or continuous measurement.

The same distinction matters when drawing a timeline on a demonstrative exhibit. Place measured points where measurements actually occurred. Label the lines between them as interpolation or modeling when that is what they represent. A smooth-looking curve should not silently imply continuous observation.

Is a nonsignificant movement difference evidence that the brain is drug-free?

Those are different hypotheses. One concerns a group comparison on a behavioral task; the other concerns chemical detection in a specimen. Answering the first does not logically resolve the second. Nor does a positive chemical result automatically answer a question about coordination, judgment or a complex real-world activity.

As original methodological commentary, the appropriate review sequence is to name the endpoint, identify the measurement supporting it, and then state the inference being proposed. If the conclusion changes from “movement declined” to “impairment ended,” ask for the additional evidence supporting that change.

How does the supplied human case literature fit?

Lemos’s supplied 2009 report describes two methamphetamine-positive driving cases with differing behavior. It is historical, selected human case evidence, not a controlled test of the mouse experiment’s timeline. The two sources can illustrate different types of evidence without being pooled into a single clock.

A forensic assessment should preserve species, route, specimen and task when comparing studies. Before applying an animal time course to a person, require a stated basis for that translation. Multiplying a mouse dose by a person’s weight is not a validation of equivalent exposure or equivalent function.

Sources and evidence type

Su H, Wang L, Huang X, et al. A combined study of pharmacodynamics and pharmacokinetics of methamphetamine and its metabolite in male mice. European Journal of Medical Research. 2026;31:133; published online December 23, 2025. Controlled animal experiment. DOI: 10.1186/s40001-025-03686-x. Publisher full text.

Lemos NP. Methamphetamine and driving. Science & Justice. 2009;49:247–249. Historical two-case report; supplied full text. DOI: 10.1016/j.scijus.2009.09.014.